查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1301042

双特异性抗体市场规模、份额、趋势分析报告：按适应症、按地区、细分市场趋势，2023-2030 年

Bispecific Antibodies Market Size, Share & Trends Analysis Report By Indication (Cancer, Inflammatory & Autoimmune disorders), By Region (North America, Europe, Asia Pacific), And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

双特异性抗体市场增长和趋势

根据 GrandView Research, Inc. 的最新报告，预计 2030 年将达到 1103 亿美元。

癌症患病率不断上升，例如乳腺癌、肺癌、前列腺癌和其他慢性疾病是市场增长的主要驱动力。 这些分子通过同时靶向癌细胞和免疫系统，提供了治疗某些类型癌症的靶向方法。 此外，对个性化医疗的需求不断增长以及向靶向治疗的转变也促进了市场的增长。

此外，製药公司和生物技术公司之间的合作和伙伴关係在推进双特异性抗体的研发方面发挥着重要作用。 这种联合研究加速了新型双特异性抗体的发现和临床开发，进一步促进了市场增长。 例如，2022 年 1 月，安进和Generate Biomedicines 签订了一项研究合作协议，针对不同治疗领域和模式的五个临床靶点发现和开发蛋白质疗法。 此外，2023年5月，美国 FDA 批准 EPKINLY (epcoritamab-bysp) 用于治疗復发或难治性瀰漫性大 B 细胞淋巴瘤 (DLBCL)。

COVID-19 大流行对双特异性抗体行业产生了双重影响。 一方面，他强调了双特异性抗体在对抗传染病方面的重要性。 然而，疫情也带来了供应链中断的挑战，导致双特异性抗体的研发被推迟。 此外，经济不确定性和预算限制可能会影响研究机构和生物技术公司，影响双特异性抗体的开发优先事项和资源分配。

此外，进入新兴国家的企业的各种发展以及产学界合作的增加正在极大地推动全球市场。 例如，2023 年 3 月，Thermo Fisher Scientific 与细胞治疗公司 Arsenal Biosciences 合作，加速和支持自体 T 细胞疗法的临床生产。

双特异性抗体市场报告亮点

  • 有迹象表明，由于全球范围内癌症的高患病率，肿瘤学领域在 2022 年以 70.4% 的份额占据市场主导地位。 此外，双特异性抗体专门针对肿瘤细胞和肿瘤相关抗原，同时不伤害健康细胞。
  • 由于治疗类风湿关节炎、牛皮癣、克罗恩病、多发性硬化症等的双特异性抗体药物的采用和开发增多，炎症和自身免疫性疾病领域将从2023 年到2030 年实现增长。预计复合年增长率将达到35.7 ％ 这些年来。
  • 凭藉高度发达的医疗基础设施和有利的政府政策，北美已在全球市场上确立了稳固的地位，到 2022 年将占据 89.5% 的市场份额。

内容

第1章调查方法及范围

  • 信息获取
  • 信息或数据分析
  • 市场范围和细分定义
  • 市场模式
    • 按公司市场份额进行市场调查
    • 区域分析

第 2 章执行摘要

  • 市场概况
  • 片段快照
  • 竞争格局快照

第3章市场变量、趋势和范围

  • 市场体系展望
    • 母公司市场前景
    • 相关/补充市场前景
  • 市场动态
    • 市场驱动因素分析
    • 市场製约因素分析
  • 行业分析工具
    • 波特五力分析
    • PESTEL 分析
    • COVID-19 感染的影响分析
  • 管道分析

第 4 章：指标业务分析

  • 双特异性抗体市场：适应症的变异分析
  • 癌症
  • 炎症和自身免疫性疾病
  • 其他

第 5 章区域业务分析

  • 2022 年和 2030 年按地区划分的双特异性抗体市场份额
  • 北美
    • 北美双特异性抗体市场，2018-2030
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲双特异性抗体市场，2018-2030
    • 英国
    • 德国
  • 亚太地区
    • 亚太地区双特异性抗体市场，2018-2030
    • 日本
    • 中国
  • 世界其他地区
    • 世界其他地区双特异性抗体市场，2018-2030

第 6 章竞争格局

  • 公司分类
  • 战略规划
  • 2022 年公司市场份额分析
  • 公司简介/列表
    • Amgen
    • Roche
    • Genentech
    • Akeso, Inc
    • Janssen
    • Taisho Pharmaceutical
    • Immunocore
Product Code: GVR-4-68040-088-4

Bispecific Antibodies Market Growth & Trends

The global bispecific antibodies market size is expected to reach USD 110.3 billion by 2030, expanding at a CAGR of 44.0% from 2023 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of cancers such as breast cancer, lung cancer, prostate cancer, and other chronic diseases is a major driver for market growth. These molecules provide a targeted approach to treat specific types of cancer by simultaneously targeting cancer cells and the immune system. Additionally, the rising demand for personalized medicine and the shift toward targeted therapies have contributed to the market's growth.

Moreover, collaborations and partnerships between pharmaceutical companies and biotechnology firms have played a crucial role in advancing bispecific antibody research and development. These collaborations have accelerated the discovery and clinical development of novel bispecific antibodies, further propelling the market growth. For instance, in January 2022, Amgen and Generate Biomedicines established a research partnership agreement to discover and develop protein therapies for five clinical targets spanning different therapeutic areas and modalities. In addition to it, in May 2023, The U.S. FDA approved EPKINLY (epcoritamab-bysp) as the inaugural bispecific antibody to be authorized for the treatment of relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL) in adult patients.

The COVID-19 pandemic has had a dual impact on the bispecific antibodies industry. On one hand, it has underscored the significance of bispecific antibodies in addressing infectious diseases. However, the pandemic has also introduced challenges in the form of supply chain disruptions, leading to delays in the research and development of bispecific antibodies. Furthermore, economic uncertainties and budget constraints have affected research institutions and biotech companies, potentially influencing their prioritization and allocation of resources towards bispecific antibody development.

Furthermore, various developments undertaken by participants, and increasing industry-academia collaborations have driven the global market to a significant extent. For instance, in March 2023, Thermo Fisher Scientific Inc collaborated with Arsenal Bioscience, a cell therapy company to facilitate and support the clinical manufacturing of Autologous T-Cell Therapies.

Bispecific Antibodies Market Report Highlights

  • By indication, the cancer segment dominated the market with a share of 70.4% in 2022, due high prevalence of cancer globally. Furthermore, bispecific antibodies specifically target tumor cells or tumor-associated antigens while sparing healthy cells
  • Inflammatory and autoimmune disorders segment is expected to grow at a significant CAGR of 35.7% during 2023-2030, owing to the increasing adoption and development of bispecific antibody drugs for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease, and multiple sclerosis among others.
  • North America established a strong regional position in the global market with an 89.5% share in 2022 due to its highly developed healthcare infrastructure and favorable government policies

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Information Procurement
  • 1.2. Information Or Data Analysis
  • 1.3. Market Scope & Segment Definition
  • 1.4. Market Model
    • 1.4.1. Market Study, By Company Market Share
    • 1.4.2. Regional Analysis

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Growing prevalence of chronic diseases
      • 3.2.1.2. Increasing investment in biologics research and development
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High development cost
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis
  • 3.4. Pipeline Analysis

Chapter 4. Indication Business Analysis

  • 4.1. Bispecific Antibodies Market: Indication Movement Analysis
  • 4.2. Cancer
    • 4.2.1. Cancer Market, 2018 - 2030 (USD Million)
  • 4.3. Inflammatory & Autoimmune Disorders
    • 4.3.1. Inflammatory & Autoimmune Disorders Market, 2018 - 2030 (USD Million)
  • 4.4. Others
    • 4.4.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Regional Business Analysis

  • 5.1. Bispecific Antibodies Market Share By Region, 2022 & 2030
  • 5.2. North America
    • 5.2.1. North America Bispecific Antibodies Market, 2018 - 2030 (USD Million)
    • 5.2.2. The U.S.
      • 5.2.2.1. Key Country Dynamics
      • 5.2.2.2. Target Disease Prevalence
      • 5.2.2.3. Competitive Scenario
      • 5.2.2.4. Regulatory Framework
      • 5.2.2.5. U.S. Bispecific Antibodies Market, 2018 - 2030 (USD Million)
    • 5.2.3. Canada
      • 5.2.3.1. Key Country Dynamics
      • 5.2.3.2. Target Disease Prevalence
      • 5.2.3.3. Competitive Scenario
      • 5.2.3.4. Regulatory Framework
      • 5.2.3.5. Canada Bispecific Antibodies Market, 2018 - 2030 (USD Million)
  • 5.3. Europe
    • 5.3.1. Europe Bispecific Antibodies Market, 2018 - 2030 (USD Million)
    • 5.3.2. UK
      • 5.3.2.1. Key Country Dynamics
      • 5.3.2.2. Target Disease Prevalence
      • 5.3.2.3. Competitive Scenario
      • 5.3.2.4. Regulatory Framework
      • 5.3.2.5. UK Bispecific Antibodies Market, 2018 - 2030 (USD Million)
    • 5.3.3. Germany
      • 5.3.3.1. Key Country Dynamics
      • 5.3.3.2. Target Disease Prevalence
      • 5.3.3.3. Competitive Scenario
      • 5.3.3.4. Regulatory Framework
      • 5.3.3.5. Germany Bispecific Antibodies Market, 2018 - 2030 (USD Million)
  • 5.4. Asia Pacific
    • 5.4.1. Asia Pacific Bispecific Antibodies Market, 2018 - 2030 (USD Million)
    • 5.4.2. Japan
      • 5.4.2.1. Key Country Dynamics
      • 5.4.2.2. Target Disease Prevalence
      • 5.4.2.3. Competitive Scenario
      • 5.4.2.4. Regulatory Framework
      • 5.4.2.5. Japan Bispecific Antibodies Market, 2018 - 2030 (USD Million)
    • 5.4.3. China
      • 5.4.3.1. Key Country Dynamics
      • 5.4.3.2. Target Disease Prevalence
      • 5.4.3.3. Competitive Scenario
      • 5.4.3.4. Regulatory Framework
      • 5.4.3.5. China Bispecific Antibodies Market, 2018 - 2030 (USD Million)
  • 5.5. Rest of the world
    • 5.5.1. Rest of the world Bispecific Antibodies Market, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Company Categorization
  • 6.2. Strategy Mapping
  • 6.3. Company Market Share Analysis, 2022
  • 6.4. Company Profiles/Listing
    • 6.4.1. Amgen
      • 6.4.1.1. Overview
      • 6.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.1.3. Product Benchmarking
      • 6.4.1.4. Strategic Initiatives
    • 6.4.2. Roche
      • 6.4.2.1. Overview
      • 6.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.2.3. Product Benchmarking
      • 6.4.2.4. Strategic Initiatives
    • 6.4.3. Genentech
      • 6.4.3.1. Overview
      • 6.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.3.3. Product Benchmarking
      • 6.4.3.4. Strategic Initiatives
    • 6.4.4. Akeso, Inc
      • 6.4.4.1. Overview
      • 6.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.4.3. Product Benchmarking
      • 6.4.4.4. Strategic Initiatives
    • 6.4.5. Janssen
      • 6.4.5.1. Overview
      • 6.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.5.3. Product Benchmarking
      • 6.4.5.4. Strategic Initiatives
    • 6.4.6. Taisho Pharmaceutical
      • 6.4.6.1. Overview
      • 6.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.6.3. Product Benchmarking
      • 6.4.6.4. Strategic Initiatives
    • 6.4.7. Immunocore
      • 6.4.7.1. Overview
      • 6.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.7.3. Product Benchmarking
      • 6.4.7.4. Strategic Initiatives

List of Tables

  • TABLE 1. List of abbreviations
  • TABLE 2. Global bispecific antibodies market, by indication, 2018 - 2030 (USD Million)
  • TABLE 3. North America bispecific antibodies market, by country, 2018 - 2030 (USD Million)
  • TABLE 4. North America bispecific antibodies market, by indication, 2018 - 2030 (USD Million)
  • TABLE 5. U.S. bispecific antibodies market, by indication, 2018 - 2030 (USD Million)
  • TABLE 6. Canada bispecific antibodies market, by indication, 2018 - 2030 (USD Million)
  • TABLE 7. Europe bispecific antibodies market, by country, 2018 - 2030 (USD Million)
  • TABLE 8. Europe bispecific antibodies market, by indication, 2018 - 2030 (USD Million)
  • TABLE 9. UK bispecific antibodies market, by indication, 2018 - 2030 (USD Million)
  • TABLE 10. Germany bispecific antibodies market, by indication, 2018 - 2030 (USD Million)
  • TABLE 11. Asia Pacific bispecific antibodies market, by country, 2018 - 2030 (USD Million)
  • TABLE 12. Japan bispecific antibodies market, by indication, 2018 - 2030 (USD Million)
  • TABLE 13. China bispecific antibodies market, by indication, 2018 - 2030 (USD Million)
  • TABLE 14. Rest of World bispecific antibodies market, by country, 2018 - 2030 (USD Million)

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information procurement
  • FIG. 3 Primary research pattern
  • FIG. 4 Market research approaches
  • FIG. 5 Value chain-based sizing & forecasting
  • FIG. 6 Market formulation & validation
  • FIG. 7 Bispecific Antibodies market segmentation
  • FIG. 8 Market snapshot, 2022
  • FIG. 9 Market trends & outlook
  • FIG. 10 Market driver relevance analysis (current & future impact)
  • FIG. 11 Market restraint relevance analysis (current & future impact)
  • FIG. 12 PESTEL analysis
  • FIG. 13 Porter's five forces analysis
  • FIG. 14 Global bispecific antibodies market: Indication movement analysis
  • FIG. 15 Global bispecific antibodies market, for cancer, 2018 - 2030 (USD Million)
  • FIG. 16 Global bispecific antibodies market, for Inflammatory & Autoimmune Disorders, 2018 - 2030 (USD Million)
  • FIG. 17 Global bispecific antibodies market, for others 2018-2030, (USD Million)
  • FIG. 18 Global bispecific antibodies market: Region movement analysis
  • FIG. 19 North America bispecific antibodies market, 2018 - 2030 (USD Million)
  • FIG. 20 U.S. bispecific antibodies market, 2018 - 2030 (USD Million)
  • FIG. 21 Canada bispecific antibodies market, 2018 - 2030 (USD Million)
  • FIG. 22 Europe bispecific antibodies market, 2018 - 2030 (USD Million)
  • FIG. 23 Germany bispecific antibodies market, 2018 - 2030 (USD Million)
  • FIG. 24 UK bispecific antibodies market, 2018 - 2030 (USD Million)
  • FIG. 25 Asia Pacific bispecific antibodies market, 2018 - 2030 (USD Million)
  • FIG. 26 Japan bispecific antibodies market, 2018 - 2030 (USD Million)
  • FIG. 27 China bispecific antibodies market, 2018 - 2030 (USD Million)
  • FIG. 28 Rest of the World bispecific antibodies market, 2018 - 2030 (USD Million)